Pumps, Pipes, and Filters: SGLT2 Inhibitors for Most Type 2 Diabetes?

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors should be considered for use in most patients with type 2 diabetes regardless of presence of atherosclerotic cardiovascular disease or history of heart failure, according to the authors of a new meta https://www.medscape.com/viewarticle/905509